Glyceryl-L-glutamine

Glyceryl-L-Glutamine: Identity, Evidence Status, and Related Science

Important Preliminary Note on the Evidentiary Status of This Name

A thorough search of peer-reviewed databases (PubMed/PMC), government health authority resources (NIH Office of Dietary Supplements, NCCIH, WHO, EMA, EFSA), official pharmacopeias, the EU Cosmetic Ingredient (CosIng) database, the Personal Care Products Council's INCI dictionary, and rigorously referenced evidence databases (Examine.com) returns no entries for "glyceryl-L-glutamine" as a distinct, registered, or independently studied compound with its own CAS number, INCI name, official monograph, clinical trial record, or pharmacopoeial entry. The term appears in a small number of commercial and marketing contexts but has not, as of the date of this article, been the subject of peer-reviewed primary research, systematic reviews, or regulatory assessment in its own right.

Accordingly, this article does three things: (1) describes what can be verified about the chemical identity and closest structural analogues of "glyceryl-L-glutamine"; (2) presents the well-established science on the parent molecule L-glutamine, which underlies any claimed biological activity; and (3) discusses the related class of glyceryl amino acid conjugates where peer-reviewed evidence does exist. All sections are clearly labeled to distinguish established science from areas where evidence for the specific compound "glyceryl-L-glutamine" is absent.

1. Identity and Chemical Classification

1.1 Parent Compound: L-Glutamine

L-glutamine (chemical formula C₅H₁₀N₂O₃) is an alpha-amino acid and one of the 20 amino acids comprising proteins. Glutamine can exist in either of two enantiomeric forms, L-glutamine and D-glutamine; the L-form is found in nature. It contains an α-amino group, which is in the protonated −NH₃⁺ form under biological conditions, and a carboxylic acid group in the deprotonated −COO⁻ form under physiological conditions.

Glutamine is the most abundant and versatile amino acid in the body. In humans, plasma contains 550–750 µM of free glutamine, representing the most abundant free amino acid in circulation. Glutamine release to the circulation and availability is mainly controlled by key metabolic organs, such as the gut, liver, and skeletal muscles.

1.2 "Glyceryl-L-Glutamine": Structural Context

The term "glyceryl-L-glutamine" denotes a conjugate of glycerol (propane-1,2,3-triol) and L-glutamine, in which the glycerol backbone is esterified or otherwise bonded to the glutamine moiety. This structural class — glyceryl amino acid esters or glyceryl amino acid conjugates — is part of a broader family of compounds that also includes glyceryl PCA (glyceryl pyrrolidone carboxylate), glyceryl glucoside, and other glycerol–nutrient conjugates that appear in cosmetic ingredient databases and patent literature. The rationale for creating such conjugates is typically to improve the water solubility, stability, or skin penetration of the parent amino acid, or to provide a slow-release vehicle. No independent CAS number, INCI entry, or regulatory registration for "glyceryl-L-glutamine" specifically has been located in the databases searched for this article.

1.3 Distinguishing "Glyceryl-L-Glutamine" from Closely Related Compounds

Several structurally related compounds are sometimes confused with "glyceryl-L-glutamine" in informal or commercial usage:

• Glycyl-L-glutamine (Gly-Gln): Glycyl-L-glutamine (C₇H₁₃N₃O₄, PubChem CID 123913) is a dipeptide consisting of the amino acid glycine bonded to L-glutamine. This is a nitrogen-containing peptide bond compound, distinct from a glycerol ester.
• Glyceryl glucoside: The chemical formula of glyceryl glucoside is C₉H₁₈O₈ (CAS 22160-26-5 / 100402-60-6); its IUPAC name is alpha-D-Glucopyranoside, 2-Hydroxy-1-(Hydroxymethyl)ethyl. This is a glycerol–glucose conjugate, not a glutamine conjugate.
• L-Glutamine (free amino acid): L-glutamine has CAS number 56-85-9, PubChem CID 5961, and molecular formula C₅H₁₀N₂O₃.

1.4 Natural Sources of L-Glutamine (the Active Parent)

Dietary sources of glutamine include especially the protein-rich foods like beef, chicken, fish, dairy products, eggs, vegetables like beans, beets, cabbage, spinach, carrots, parsley, vegetable juices and also wheat, papaya, Brussels sprouts, celery, kale, and fermented foods like miso.

Glutamine is mainly synthesized endogenously by the enzyme glutamine synthetase (GS) and hydrolyzed by the enzyme glutaminase (GLS). GS catalyzes glutamine biosynthesis using glutamate and ammonia (NH₃) as a source, consuming one ATP in the reaction.

2. Traditional and Historical Use

Because "glyceryl-L-glutamine" as a specific chemical entity has no documented history as an isolate or preparation in traditional medicine, ethnobotany, or historical pharmacopoeia, no traditional or historical use can be attributed to this compound specifically. The compound exists, if at all, as a modern synthetic or semi-synthetic derivative developed within the contemporary cosmetic or nutraceutical industry.

L-glutamine itself, as a naturally occurring amino acid abundant in food proteins, has been consumed as part of dietary protein throughout human history; however, its isolation, characterization, and intentional supplementation are modern phenomena arising from mid-twentieth-century amino acid biochemistry. Glutamine is the most abundant amino acid in the body and is one of the most widely researched amino acids, with multiple clinical trials on various aspects of medical nutritional care including gastrointestinal disease, oncology, burn-trauma, HIV/AIDS, and chronic wound management. This research tradition began in earnest in the 1980s and 1990s with the recognition of glutamine as a conditionally essential nutrient in critical illness.

3. Key Constituents and Established Mechanisms of Action of L-Glutamine

Because the biological plausibility of any "glyceryl-L-glutamine" supplement rests on its ability to release or mimic L-glutamine in biological tissues, the established mechanisms of L-glutamine are the relevant scientific foundation. No independent mechanism data exist for the glyceryl conjugate itself.

3.1 Roles in Intermediary Metabolism

Glutamine participates in numerous functional activities in cells, including being a substrate for protein synthesis, ureogenesis in the liver, and for hepatic and renal gluconeogenesis. Glutamine has been shown to be a precursor for neurotransmitter synthesis, nucleotide and nucleic acid synthesis, and glutathione production. In addition, glutamine is an oxidative fuel for the immune system, a major source of nitrogen for purine and pyrimidine biosynthesis, and a nitrogen transporter between organs.

3.2 Intestinal Barrier Function

Glutamine is vital for the rapidly proliferating enterocytes lining the intestinal mucosa and promotes the expression of proteins in the tight junctions, strengthening the barrier function and reducing gut permeability. With excessive physical activity, malnutrition, acute and chronic illnesses, sarcopenia, or prolonged fasting, plasma glutamine levels drop. When glutamine is depleted, the small intestine atrophies, causing increased gut permeability and bacterial translocation.

In gut physiology, glutamine promotes enterocyte proliferation, regulates tight junction proteins, suppresses pro-inflammatory signaling pathways, and protects cells against apoptosis and cellular stresses during normal and pathologic conditions.

3.3 Immune Function

In health and disease, the rate of glutamine consumption by immune cells is similar to or greater than glucose. In vitro and in vivo studies have determined that glutamine is an essential nutrient for lymphocyte proliferation and cytokine production, macrophage phagocytic plus secretory activities, and neutrophil bacterial killing.

3.4 Glutathione Synthesis

Glutamine is a conditionally essential amino acid in critical illness. It is crucial in maintaining immune cell function, intestinal barrier integrity, antioxidant defense, and modulation of systemic inflammation. The link to antioxidant defense operates through glutamine's role as a precursor to glutathione, the body's principal intracellular antioxidant tripeptide.

3.5 Aquaporin and Skin Hydration

Glutamine is one of six amino acids that function as components of the natural moisturizing factor (NMF) in skin. Natural moisturizing factors (NMFs) are filaggrin-derived components in the cornified layer that are critical for maintaining healthy skin moisturization and barrier function. Histidine, glutamine, and arginine are metabolites of filaggrin in the stratum corneum (SC) that are metabolized into trans-urocanic acid, pyrrolidone carboxylic acid, and citrulline, respectively. The largest component (~40%) of NMF is free amino acids.

Research on NMF quantification showed that subjects with higher levels of six amino acids — alanine, arginine, asparagine, glutamine, glycine, and histidine — exhibited significantly higher skin hydration than those with lower amino acid levels. The six-amino-acid NMF level peaked in subjects aged 25–29 and then gradually and significantly decreased with age.

4. Scientific Evidence by Area of Application (L-Glutamine)

The following sections concern the clinical evidence for L-glutamine supplementation, not for "glyceryl-L-glutamine" specifically, for which no published clinical trials were identified. Evidence strength is characterized per the available literature.

4.1 Intestinal Permeability and Gut Barrier

Evidence strength: Moderate, context-dependent; mixed across populations.

A systematic review and meta-analysis found that short-term (less than 2 weeks) glutamine supplementation in higher dosages (>30 g/day) had a significant reductive effect on gut permeability. The meta-analysis demonstrated a significant reduction in intestinal permeability with glutamine supplementation exceeding 30 g/day for durations of less than 2 weeks.

A randomized, double-blind, placebo-controlled trial enrolled 80 critically ill patients between April and October 2017 from the general ICU of a university hospital to evaluate the effects of early enteral glutamine supplementation on intestinal permeability. Enteral administration of glutamine has been proposed as an effective means of recovering intestinal barrier function. This amino acid has a modulating effect on reducing bacterial translocation, which can influence immune functions of the intestine.

One study demonstrated that 60 minutes of high-intensity running (70% V̇O₂max) caused an increase in intestinal permeability that was completely ameliorated in the glutamine trial, demonstrating the protective effects of glutamine supplementation on the gut. This study showed that oral glutamine supplementation in humans reduces exercise-induced intestinal permeability.

In a randomized controlled trial, Benjamin et al. reported that glutamine supplementation (0.5 g/kg body weight; 2 months) in patients with Crohn's disease in remission phase reduced intestinal permeability and morphology. However, a number of studies did not observe any improved outcomes.

Glutamine supplementation was investigated for its possible effects in critically ill people or after abdominal surgery, but the low quality of research prevented conclusions about any effect. Supplementation does not appear to have an effect in infants with significant stomach or intestinal disorders.

4.2 Critical Illness, Surgical Patients, and Trauma

Evidence strength: Mixed to uncertain at high doses; benefit suggested in moderate-dose enteral and parenteral settings but contradicted by large trials at very high doses.

More than a dozen clinical studies have suggested that the provision of parenteral or enteral glutamine supplementation in both critically ill and surgical patients may improve nitrogen balance, constitutive protein levels, and immune function, while decreasing infection rates, length of hospital stay, and mortality rates. However, there is much discrepancy across single randomized controlled trials comparing effects on clinical endpoints such as infection rates, length of stay, and mortality.

The apparent effect of glutamine supplementation in reducing the incidence of infectious complications in critically ill and surgical patients is probably due to glutamine's role as the preferred fuel for enterocytes, for maintaining gastrointestinal structure and decreasing gut mucosal atrophy, which could otherwise lead to increased intestinal permeability and bacterial translocation.

Safety signal at very high doses: An umbrella review of meta-analyses noted that the REDOX study indicated that critically ill patients given glutamine doses of >0.5 g/kg/day had higher urea concentrations and higher mortality rates. Conflicting data regarding the potential harm of high-dose glutamine administration in critically ill patients from the REDOXS and METAPLUS trials are a matter of ongoing discussion in the clinical nutrition literature.

4.3 Exercise Performance and Recovery

Evidence strength: Preliminary; limited human trials.

In a randomized controlled trial in athletes who received oral glutamine supplementation 2 hours before exercise, glutamine attenuated gastrointestinal permeability compared to placebo, with larger doses being more effective. The broader literature on glutamine for muscle recovery and exercise performance is mixed, and definitive conclusions regarding ergogenic benefit have not been established in systematic reviews.

4.4 Skin Hydration and Barrier Function (Topical Amino Acids)

Evidence strength: Preliminary; largely in vitro or observational; no published clinical trials specifically on topical "glyceryl-L-glutamine."

Natural moisturizing factor (NMF) is found inside keratinocytes and helps regulate stratum corneum hydration. Constituents of NMF include lactic acid, urea, inorganic ions, and amino acids including glutamine; the osmotically active and humectant properties of NMF allow the epidermis to retain hydration even in dry environments.

NMF is intracellular and, at this time, it is not known whether exogenously applied NMF or its precursors would result in increased NMF levels. This is a critical limitation when assessing the efficacy of topically applied glutamine or its derivatives, including any glyceryl-L-glutamine conjugate.

Atopic dermatitis, psoriasis, ichthyosis vulgaris, and xerosis all give rise to dry and flaky skin. In patients suffering from these conditions, the levels of NMF in the stratum corneum are either reduced or absent. Aging, routine soap washing of the skin, and excessive exposure to UV light have also been shown to deplete the levels of NMF from the superficial layers of the stratum corneum.

4.5 Inflammatory Bowel Disease

Evidence strength: Insufficient for clinical recommendation.

Two clinical trials found that taking glutamine supplements did not improve symptoms of Crohn's disease, despite observational evidence that patients with inflammatory bowel disease may have reduced glutamine availability. As glutamine stores are depleted during severe metabolic stress including trauma, sepsis, and inflammatory bowel diseases, glutamine supplementation has been examined in patients to improve clinical outcomes, but the results remain inconclusive for IBD specifically.

5. Body Systems and Health Areas Associated with L-Glutamine

• Gastrointestinal system: Enterocyte fuel, tight junction protein regulation, gut barrier integrity, bacterial translocation prevention.
• Immune system: The rate of glutamine consumption by immune cells is similar to or greater than glucose; glutamine is essential for lymphocyte proliferation and cytokine production, macrophage phagocytic activity, and neutrophil bacterial killing.
• Musculoskeletal system: Nitrogen carrier and substrate for protein synthesis; studied in athletes and critically ill patients for muscle catabolism prevention.
• Skin (integumentary system): NMF component; role in hydration via filaggrin metabolism and possible influence on aquaporin-3 expression.
• Central nervous system: Glutamine has been shown to be a precursor for neurotransmitter synthesis.
• Hepatic and renal systems: Glutamine participates in ureogenesis in the liver and in hepatic and renal gluconeogenesis.
• Antioxidant defense: Glutamine as a precursor to glutathione is relevant to oxidative stress protection in multiple tissues.

6. Dosage Forms and Reported Dosages

The following dosages pertain exclusively to L-glutamine as studied in peer-reviewed clinical trials. No dosage data exist for "glyceryl-L-glutamine" in peer-reviewed literature.

• Oral supplementation (powder/capsule): Glutamine supplementation studies showing significant effects on gut permeability have generally used dosages greater than 30 g/day for durations of less than two weeks in short-term clinical protocols.
• Body-weight–adjusted dosing in IBD: In one randomized controlled trial in Crohn's disease patients in remission, glutamine was supplemented at 0.5 g/kg body weight for 2 months.
• Critical illness upper bound: The REDOX study used doses of >0.5 g/kg/day (intravenous) in critically ill patients, which was associated with adverse outcomes including higher mortality in that specific critically ill population.
• Parenteral/enteral clinical nutrition: The use of intravenous glutamine is well established in critical medicine for increasing depressed glutamine plasma levels and averting intestinal atrophy.
• Animal model comparator (not human): In piglet studies, glutamine was supplemented at 0.81% of the basal diet.
• Glycyl-glutamine dipeptide in animals: In a piglet study of the dipeptide glycyl-glutamine, 240 piglets were randomly assigned to receive a basal diet supplemented with 0.25% Gly-Gln for 3 weeks.

7. Safety Considerations and Interactions

The following safety data apply to L-glutamine as documented in peer-reviewed literature and regulatory assessments. No independent safety data for "glyceryl-L-glutamine" have been identified.

7.1 General Safety Profile of Oral L-Glutamine

Of 22 meta-analyses reviewed in one umbrella analysis, six noted that no side effects were observed with glutamine supplementation; the remaining five analyses flagged the REDOX trial's finding that critically ill patients receiving glutamine doses >0.5 g/kg/day had higher urea concentrations and higher mortality rates. This adverse signal is specific to high-dose parenteral use in multi-organ failure patients and should not be generalized to typical oral supplementation in healthy individuals.

7.2 Topical Safety (L-Glutamine as a Cosmetic Ingredient)

Scientific assessments by the Cosmetic Ingredient Review (CIR) Expert Panel categorize L-glutamine as "safe as used" in cosmetic products. Because it is a skin-identical ingredient and a naturally occurring amino acid, it exhibits high biocompatibility and a very low sensitization potential.

7.3 Glutamine in Critical Illness: Dose-Dependent Risk

Burn disease induces a persistent hypermetabolic response characterized by pronounced protein and energy deficiency, loss of muscle mass, and marked glutamine depletion. Glutamine is a conditionally essential amino acid in critical illness. However, as noted above, very high intravenous doses in severely ill patients with multi-organ dysfunction have been associated with harm in large randomized controlled trials, underscoring the importance of dose and route of administration.

7.4 Stability Considerations

Glutamine is not included in traditional total parenteral nutrition (TPN) formulations because of its instability in aqueous solutions. In particular, glutamine breaks down in aqueous solution to form pyroglutamic acid with a release of toxic ammonia. Hence, TPN solutions containing glutamine which are stored even for short lengths of time can accumulate toxic ammonia. This chemical instability of free glutamine in aqueous solution is, in fact, one of the pharmaceutical motivations for creating conjugates such as glycyl-glutamine or potentially glyceryl-glutamine, as structural modification can improve solubility and stability. However, no published data confirming the stability advantage of a glyceryl-L-glutamine conjugate specifically were identified in this review.

7.5 Known Interactions

No specific drug–nutrient interactions have been documented for "glyceryl-L-glutamine" in peer-reviewed literature. For L-glutamine broadly, potential considerations noted in the clinical literature include: the possibility of elevating ammonia in patients with hepatic encephalopathy (since glutamine is an ammonia carrier), and the adverse outcomes at high intravenous doses in multi-organ dysfunction as discussed above.

8. Conclusion: Evidentiary Summary

"Glyceryl-L-glutamine" as a named compound does not currently possess an independent peer-reviewed evidence base, regulatory registration, official monograph, or established clinical use profile. The scientific and regulatory literature that does exist pertains to its structural components — L-glutamine (extensively studied) and glycerol (well-characterized humectant and excipient) — and to structurally similar but distinct conjugates such as glycyl-L-glutamine (a dipeptide studied in animal models of weaning stress) and glyceryl glucoside (studied as a cosmetic humectant with aquaporin-3 activity).

Any product marketed under the name "glyceryl-L-glutamine" would, based on structural logic, be expected to rely on the biology of L-glutamine for its mechanisms of action. The parent molecule has moderate clinical evidence supporting its role in gut barrier maintenance (particularly at doses >30 g/day short-term in clinical settings), well-documented biochemical roles in immune function, protein synthesis, and glutathione production, and a recognized position as one of the free amino acid components of skin NMF. Whether a glyceryl ester or glyceryl conjugate meaningfully alters the bioavailability, skin penetration, or stability of glutamine compared to the free amino acid remains, as of this writing, an open and unstudied question in the peer-reviewed literature.

References

• PubChem: L-Glutamine (CID 5961) — National Library of Medicine, NIH
• PubChem: Glycyl-L-glutamine (CID 123913) — National Library of Medicine, NIH
• Wikipedia: Glutamine — structural, biochemical, and supplementation overview
• Cruzat V et al. (2018). Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation. Nutrients. PMC6266414.
• Stehle P et al. (2017). Therapeutic benefits of glutamine: An umbrella review of meta-analyses. Clinical Nutrition ESPEN. PMC5454963.
• Stehle P et al. Umbrella review of meta-analyses on glutamine supplementation, PMC5431459.
• Systematic review and meta-analysis: glutamine supplementation and gut permeability in adults. Amino Acids. PMC11471693.
• Springer Nature: A systematic review and meta-analysis of clinical trials on the effects of glutamine supplementation on gut permeability in adults. Amino Acids, 2024.
• Shariatpanahi ZV et al. (2019). Effects of Early Enteral Glutamine Supplementation on Intestinal Permeability in Critically Ill Patients. Indian Journal of Critical Care Medicine. PMC6709840.
• Design, synthesis and characterization of linear unnatural amino acids for skin moisturization. International Journal of Cosmetic Science. PMC5244679.
• Pugh JN et al. (2014). Effects of oral glutamine supplementation on exercise-induced gastrointestinal permeability and tight junction protein expression. European Journal of Applied Physiology. PMC3921361.
• Effects of Dietary L-Glutamine Supplementation on the Intestinal Function and Muscle Growth of Piglets. Animals. PMC10972121.
• Modulation of Gut Microbial Community and Metabolism by Dietary Glycyl-Glutamine Supplementation in Piglets. PMC7025575.
• Roles of Glutamine in the Intestine and Its Implication in Intestinal Diseases. PMC5454963 / PMC5431459.
• McGraw Hill Medical / AccessDermatologyDxRx: Natural Moisturizing Factor chapter in Cosmeceuticals and Cosmetic Ingredients.
• Practical Dermatology: Understanding the Role of Natural Moisturizing Factor in Skin Hydration.
• SCIRP: Six Amino Acids among Natural Moisturizing Factors Responsible for Skin Hydration. Journal of Cosmetics, Dermatological Sciences and Applications, 2024.
• Shabert JK (2002). Glutamine supplementation: Heal the gut, help the patient. Nutrition in Clinical Practice. PubMed PMID 11840007.
• SpecialChem CosIng: GLYCERYL GLUCOSIDE — INCI ingredient database entry.